DECIPHERA PHARMACEUTICALS, INC.

DCPHUnited States

27 filed reports · 333 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$163M

FY2023 · to Dec 31, 2023

up +21.9% vs $134M

10-K

Net income

-$195M

FY2023 · to Dec 31, 2023

a year earlier: -$179M

10-K

Operating income

-$211M

FY2023 · to Dec 31, 2023

a year earlier: -$183M

10-K

Latest quarter

Revenue

$45M

Q1 FY2024 · to Mar 31, 2024

up +34.5% vs $33.4M

10-Q

Net income

-$45.1M

Q1 FY2024 · to Mar 31, 2024

a year earlier: -$49.6M

10-Q

Operating income

-$48.8M

Q1 FY2024 · to Mar 31, 2024

a year earlier: -$53.3M

10-Q

Filed reports

27 reports · Sep 2017 to Mar 2024

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR202,154Sep 2017 to Mar 2024
Annual · 10-KSEC EDGAR72,327Dec 2017 to Dec 2023

Documents

PeriodTypePeriod endPublishedFactsSource
FY2024 Q110-Q2024-03-312024-05-10266Open
FY202310-K2023-12-312024-02-07656Open
FY2023 Q310-Q2023-09-302023-10-30168Open
FY2023 Q210-Q2023-06-302023-08-09153Open
FY2023 Q110-Q2023-03-312023-05-03102Open
FY202210-K2022-12-312023-02-07320Open
FY2022 Q310-Q2022-09-302022-11-03110Open
FY2022 Q210-Q2022-06-302022-08-04104Open
FY2022 Q110-Q2022-03-312022-05-0499Open
FY202110-K2021-12-312022-02-08330Open
FY2021 Q310-Q2021-09-302021-11-02101Open
FY2021 Q210-Q2021-06-302021-08-0392Open

Financial data

333 concepts · 4,481 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial328 concepts · 4,375 facts · Dec 2015 to Mar 2024

  • Net income loss42 · Dec 2015 to Mar 2024
  • Operating income loss42 · Dec 2015 to Mar 2024
  • Revenue42 · Dec 2015 to Mar 2024
  • Allocated share based compensation expense38 · Dec 2015 to Mar 2024
  • Cash and cash equivalents at carrying value38 · Dec 2015 to Mar 2024
  • Depreciation depletion and amortization38 · Dec 2015 to Mar 2024
  • Increase decrease in accounts payable38 · Dec 2015 to Mar 2024
  • Increase decrease in prepaid deferred expense and other assets38 · Dec 2015 to Mar 2024
  • Nonoperating income expense38 · Dec 2015 to Mar 2024
  • Other nonoperating income expense38 · Dec 2015 to Mar 2024
  • Payments to acquire property plant and equipment38 · Dec 2015 to Mar 2024
  • Research and development expense38 · Dec 2015 to Mar 2024
  • Share based compensation38 · Dec 2015 to Mar 2024
  • Stockholders equity (US GAAP)38 · Dec 2015 to Mar 2024
  • Cash cash equivalents restricted cash and restricted cash equivalents36 · Dec 2016 to Mar 2024
  • Accounts payable current35 · Dec 2016 to Mar 2024
  • Accrued professional fees current35 · Dec 2016 to Mar 2024
  • Assets35 · Dec 2016 to Mar 2024
  • Assets current35 · Dec 2016 to Mar 2024
  • Employee related liabilities current35 · Dec 2016 to Mar 2024
  • Liabilities35 · Dec 2016 to Mar 2024
  • Liabilities and stockholders equity35 · Dec 2016 to Mar 2024
  • Liabilities current35 · Dec 2016 to Mar 2024
  • Net cash provided by used in financing activities35 · Dec 2016 to Mar 2024

Product1 concept · 100 facts · Dec 2018 to Mar 2024

  • Revenue100 · Dec 2018 to Mar 2024

Geography4 concepts · 6 facts · Dec 2017 to Dec 2019

  • Number Of Lease Agreement3 · Dec 2017 to Dec 2019
  • Additional Number Of Lease Agreements1 · Dec 2019
  • Lessee, Operating Lease, Number Of Renewal Options1 · Dec 2019
  • Operating lease payments1 · Dec 2017

Segments

106 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service2 members · 100 facts

  • Product revenues, net73 · Dec 2018 to Mar 2024
  • Collaboration revenues27 · Dec 2018 to Mar 2024

Statement geographical2 members · 6 facts

  • Kansas(KS) [Member]5 · Dec 2017 to Dec 2019
  • Massachusetts [Member]1 · Dec 2019

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of DECIPHERA PHARMACEUTICALS, INC. (DCPH) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.